Home / Treatments / OON Acad Ctr Ref
OON Acad Ctr Ref denials: what the review data shows
Independent reviewers have decided 33 published cases where an insurer denied OON Acad Ctr Ref — and they overturned the insurer 42.4% of the time. A denial for OON Acad Ctr Ref is a starting position, not a final answer.
Published decisions
33
2001–2026
Overturned
42.4%
14 denials reversed
Conditions behind oon acad ctr ref denials
What insurers denied — and how those fights ended.
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 25 | 44% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 7 | 28.6% |
Typical time to a decision
7 days
Most land between 4 and 21 days
Handled as urgent
60.6%
Expedited when a delay would cause harm
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
A 64-year-old male enrollee has requested reimbursement for services provided on an emergent basis. Findings: The physician reviewer found that the patient is a 64-year-old male who underwent urgent/emergent evaluation, resuscitation and bladder tumor resection and fulguration. The pathology specimen showed high grade transitional cell carcinoma and although the operative report states resection was carried out through to the perivesical fat, no muscle was found on pathology to assess the depth of tumor penetration for accurate staging and planning of treatment options. The patient underwent an out-of-network resection six weeks later on the date in question and was found to have no muscle invasion. He is seeking coverage for the out-of-network procedure on the grounds that it was required on an emergent basis.
The patient is a 49-year-old man who has a PSA of 16.6 and a Gleason score of 3+4=7. His bone scan and CT scans of the pelvis and abdomen are both negative for metastases. The patient is sexually active. His prostate is 19cc (reasonably small). The cancer is mostly on the right side of the prostate. The patient’s prostate cancer occupies 20-50% of the right lobe. The patient has obtained consultations from multiple providers; he has decided high definition radiation and external radiotherapy with implants is the most appropriate treatment for his condition. The Health Plan has denied authorization for the proposed therapy on the basis it is not medically necessary for treatment of the patient’s medical condition.This patient has marginally advanced prostate cancer with close to 50% of the volume of the right lobe being involved.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Physician 1: The patient was diagnosed with chronic lymphocytic leukemia (CLL) in 2000. He was initially treated with chemotherapy and immunotherapy. A bone marrow biopsy in June 2005 revealed relapse of the CLL as well as myelodysplasia. It was recommended that he undergo bone marrow transplantation but no HLA-identical match, either related or unrelated could be found. The patient then went to Israel and received a haploidentical graft from his daughter. The patient died in October 2005.At issue is whether haploidentical stem cell transplantation was likely to be more beneficial for the patient than any available standard therapy.The standard transplant for myelodysplasia is an allogeneic transplant with HLA-identical stem cells, either from a relative or an unrelated donor. Unfortunately, no such match can be found in many patients, as was the case here.
The patient is a 61-year-old male diagnosed with prostate cancer by his urologist (stage T2a, PSA of 10.2, and a Gleason score of 3+4=7). The patient was referred to a radiation oncologist for discussion of radiation options and was seen on 9/22/04. According to the consult note, examination of the prostate identified a small nodule in the right side of the gland, which was “highly suspicious for capsular involvement.” Clinical evidence of capsular invasion, therefore, resulted in a stage of T3a. Options were discussed including initial hormone therapy (LHRH agonist) followed by either external beam irradiation (with a dose of 7000 cGy given to the prostate) or combined external beam and permanent iodine seed implant (brachytherapy). The patient has requested authorization for treatment with proton beam therapy as he believes it is the most appropriate treatment for his condition.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for OON Acad Ctr Refwhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.